In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Neuroscience Letters

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 16644116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease

  2005cited by this paper
• Gamma-glutamylcysteine ethyl ester-induced up-regulation of glutathione protects neurons against Abeta(1-42)-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease.

  2005cited by this paper
• Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease

  2005cited by this paper
• Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO‐mediated pathway not involving peroxynitrite: implications for Parkinson's disease

  2005cited by this paper
• Glutathione Metabolism during Aging and in Alzheimer Disease

  2004cited by this paper
• Glutathione precursors replenish decreased glutathione pool in cystinotic cell lines.

  2004cited by this paper
• Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

  2003cited by this paper
• Elevation of brain glutathione by γ‐glutamylcysteine ethyl ester protects against peroxynitrite‐induced oxidative stress

  2002cited by this paper
• Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.

  2002cited by this paper
• Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier.

  2001cited by this paper
• Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity

  2000cited by this paper
• Redox signaling and the emerging therapeutic potential of thiol antioxidants.

  1998cited by this paper
• Oxidative mechanisms in nigral cell death in Parkinson's disease.

  1998cited by this paper
• Effect of Buthionine Sulfoximine, a Synthesis Inhibitor of the Antioxidant Glutathione, on the Murine Nigrostriatal Neurons

  1996cited by this paper
• Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones

  1996cited by this paper
• Reduced intravenous glutathione in the treatment of early Parkinson's disease.

  1996cited by this paper
• Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines.

  1996cited by this paper
• Neuropathology of Parkinson's Disease

  1996cited by this paper
• THIOL REDUCING AGENTS MODULATE INDUCED APOPTOSIS IN PORCINE ENDOTHELIAL CELLS

  1994cited by this paper
• Establishment and characterization of immortalized clonal cell lines from fetal rat mesencephalic tissue

  1994cited by this paper
• Glutathione-ascorbic acid antioxidant system in animals.

  1994cited by this paper
• Glutathione deficiency leads to mitochondrial damage in brain.

  1991cited by this paper
• Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients.

  1986cited by this paper
• Glutathione.

  1983cited by this paper
• Parkinson's disease: A disorder due to nigral glutathione deficiency?

  1982cited by this paper

• Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases

  2023cites this paper
• Opioids Alleviate Oxidative Stress via the Nrf2/HO-1 Pathway in LPS-Stimulated Microglia

  2023cites this paper
• Glutathione ethyl ester reverses the deleterious effects of fentanyl on ventilation and arterial blood-gas chemistry while prolonging fentanyl-induced analgesia

  2021cites this paper
• Using the Oxytosis/Ferroptosis Pathway to Understand and Treat Age-Associated Neurodegenerative Diseases.

  2020cites this paper
• Fidelity of the PINK1 Knockout Rat to Oxidative Stress and Other Characteristics of Parkinson Disease.

  2020cites this paper
• STUDIES OF OXIDATIVE DAMAGE, BRAIN PROTEOME, AND NEUROCHEMICAL METABOLITES IN COGNITIVE AND NEURODEGENERATIVE DISORDERS: (1) CHEMOTHERAPY-INDUCED COGNITIVE IMPAIRMENT; (2) PARKINSON DISEASE RAT MODEL

  2019cites this paper
• Profiles of brain oxidative damage, ventricular alterations, and neurochemical metabolites in the striatum of PINK1 knockout rats as functions of age and gender: Relevance to Parkinson disease.

  2019cites this paper
• Heritability of the aged glutathione phenotype is dependent on tissue of origin

  2018cites this paper
• Post-translational Activation of Glutamate Cysteine Ligase with Dimercaprol

  2017cites this paper
• Protective effects of fisetin and other berry flavonoids in Parkinson's disease.

  2017cites this paper
• The Antioxidant Effects of Thymoquinone in Activated BV-2 Murine Microglial Cells

  2016cites this paper
• Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.

  2016cites this paper
• Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs.

  2015cites this paper
• Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases.

  2015cites this paper
• Redox proteomics and the dynamic molecular landscape of the aging brain.

  2014cites this paper
• Mitochondrial dysfunction in psychiatric and neurological diseases: Cause(s), consequence(s), and implications of antioxidant therapy

  2013cites this paper
• The concentration of glutathione in human erythrocytes is a heritable trait.

  2013cites this paper
• Thiol-Redox Signaling, Dopaminergic Cell Death, and Parkinson's Disease

  2012cites this paper
• Biomarkers of protein oxidation in human disease.

  2012cites this paper
• A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson's Disease

  2012cites this paper
• Cocaine-Induced Adaptations in Cellular Redox Balance Contributes to Enduring Behavioral Plasticity

  2011cites this paper
• S-Glutathionylation: From Molecular Mechanisms to Health Outcomes

  2011cites this paper
• SÄDE VIIRLAID Novel glutathione analogues and their antioxidant activity

  2011cites this paper
• Gamma‐glutamylcysteine ethyl ester protects cerebral endothelial cells during injury and decreases blood–brain barrier permeability after experimental brain trauma

  2011cites this paper
• Potential neuroprotective effect of γ-glutamylcysteine ethyl ester on rat brain against kainic acid-induced excitotoxicity

  2010cites this paper
• Prodrug Approach for Increasing Cellular Glutathione Levels

  2010cites this paper
• A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease.

  2009cites this paper
• Inhibition of platelet aggregation by 1-methyl-4-phenyl pyridinium ion (MPP+) through ATP depletion: Evidence for the reduced platelet activities in Parkinson's disease

  2009cites this paper
• Proteomics in animal models of Alzheimer's and Parkinson's diseases.

  2009cites this paper
• Glutathione—a review on its role and significance in Parkinson's disease

  2009cites this paper
• In vivo amelioration of adriamycin induced oxidative stress in plasma by gamma-glutamylcysteine ethyl ester (GCEE).

  2009cites this paper
• Characterization of UPF peptides, members of the glutathione analogues library, on the basis of their effects on oxidative stress-related enzymes

  2009cites this paper
• Antioxidative and anti-inflammatory protection of oleanolic acid and ursolic acid in PC12 cells.

  2008cites this paper
• Proteome analysis of human substantia nigra in Parkinson's disease

  2008cites this paper
• Redox imbalance in Parkinson's disease.

  2008cites this paper
• Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb.

  2007cites this paper
• 1-methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons.

  2007cites this paper
• Inducible Alterations of Glutathione Levels in Adult Dopaminergic Midbrain Neurons Result in Nigrostriatal Degeneration

  2007influential citation
• Neurotoxins and neurotoxicity mechanisms. an overview

  2006cites this paper